Whittier Trust’s Amicus Therapeutics FOLD Stock Holding History

Whittier Trust’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-356	Closed	-$3.95K	–	1584
2023 Q1	$3.95K	Hold	356	–	–	﹤0.01%	1422
2022 Q4	$4.35K	Hold	356	–	–	﹤0.01%	1403
2022 Q3	$4K	Hold	356	–	–	﹤0.01%	1480
2022 Q2	$4K	Hold	356	–	–	﹤0.01%	1472
2022 Q1	$3K	Hold	356	–	–	﹤0.01%	1514
2021 Q4	$4K	Hold	356	–	–	﹤0.01%	1434
2021 Q3	$3K	Hold	356	–	–	﹤0.01%	1379
2021 Q2	$3K	Hold	356	–	–	﹤0.01%	1406
2021 Q1	$4K	Hold	356	–	–	﹤0.01%	1371
2020 Q4	$8K	Hold	356	–	–	﹤0.01%	1178
2020 Q3	$5K	Hold	356	–	–	﹤0.01%	1226
2020 Q2	$5K	Hold	356	–	–	﹤0.01%	1165
2020 Q1	$3K	Hold	356	–	–	﹤0.01%	1297
2019 Q4	$3K	Hold	356	–	–	﹤0.01%	1307
2019 Q3	$3K	Buy	+356	New	+$3.86K	﹤0.01%	1322
2019 Q1	–	Sell	-30	Closed	–	–	1445
2018 Q4	$0	Buy	+30	New	+$330	﹤0.01%	1351

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Whittier Trust's FOLD Position: Q2 2023 in Review

Whittier Trust sold out of Amicus Therapeutics (FOLD) in Q2 2023, closing a stake of 356 shares — an estimated $3.95K sold.

Whittier Trust first reported a position in FOLD in Q4 2018 and held it in 16 quarters. The position peaked at $8K in Q4 2020. 216 funds tracked by Wall St. Rank hold FOLD as of Q2 2023.

Whittier Trust reported no remaining Amicus Therapeutics position as of Q2 2023 after selling out during the quarter.
Whittier Trust sold 356 Amicus Therapeutics shares in Q2 2023, an estimated $3.95K.
Whittier Trust first reported a position in Amicus Therapeutics in Q4 2018 and held it in 16 quarters.
Whittier Trust's Amicus Therapeutics position peaked at $8K in Q4 2020.
216 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2023.

Based on Whittier Trust's 13F filing for Q2 2023, filed 24 Jul 2023.